Abstract

Purpose: Inflammatory breast cancer (IBC) is a rare but aggressive type of advanced breast cancer. Epidermal growth factor receptor (EGFR) expression is an independent poor prognostic factor in IBC. The purpose of this study was to determine the effect on IBC tumorigenicity and metastasis of blocking the EGFR pathway.

Experimental Design: IBC cell lines, which express high level of EGFR, were treated with EGFR small interfering RNA and with the EGFR tyrosine kinase inhibitor erlotinib. The role of EGFR in IBC cell proliferation, motility, invasiveness, and change of the expression levels of epithelial-mesenchymal transition markers was examined. The role of extracellular signal–regulated kinase (ERK)-1/2 in erlotinib activity was also studied. The activity of erlotinib in tumor growth and metastasis was examined in an orthotopic xenograft model of IBC.

Results: Erlotinib inhibited proliferation and anchorage-independent growth of IBC cells, and this inhibition was ERK dependent. Erlotinib inhibited cell motility and invasiveness and reversed the mesenchymal phenotype of IBC cells to epithelial phenotype in three-dimensional culture. Erlotinib dramatically inhibited IBC tumor growth in a xenograft model. Interestingly, erlotinib inhibited spontaneous lung metastasis, even at a low dose that had no significant effect on primary tumor growth. These erlotinib-treated tumors were converted to epithelial phenotype from mesenchymal phenotype.

Conclusions: The EGFR pathway is involved in tumor growth and metastasis of IBC. Targeting EGFR through the ERK pathway may represent an effective therapeutic approach to suppress tumorigenicity and prevent metastasis in EGFR-expressing IBC.

Inflammatory breast cancer (IBC) is a rare but very aggressive type of advanced breast cancer that accounts for 1% to 5% of all breast cancer cases in the United States (1, 2). IBC can initially present as either stage IIIB locally advanced or stage IV breast cancer (3). IBC is characterized by extensive lymphovascular invasion and is associated with a high risk of distant metastases (4). Even when treated with multimodality strategies including chemotherapy, surgery, and radiation therapy, IBC is associated with a poor long-term outcome and a high risk of recurrence and metastasis compared with noninflammatory locally advanced breast cancer. The 3-year survival rate among IBC patients is only about 40%, much lower than the 85% 3-year survival rate among patients with non-IBC (5). To date, effective standard therapies for IBC are limited. Therefore, novel therapeutic approaches need to be developed. Studying the biological basis of IBC will allow us to develop novel targeted therapies to improve the outcome of IBC.

It is reported that up to 30% of IBC patients have distant metastases at the time of diagnosis, in contrast to 5% of
patients with non-IBC (6). The lower survival rate of patients with IBC is thought to be due to the highly metastatic nature of the disease. An important event during malignant tumor progression and metastasis is epithelial-mesenchymal transition (EMT), a process by which cells undergo a morphologic switch from a polarized epithelial phenotype to a mesenchymal fibroblastoid phenotype (7–9). EMT is characterized by the loss of epithelial markers (E-cadherin and cytokeratins) and the presence of mesenchymal markers (vimentin and fibronectin). Evidence of the importance of EMT in metastasis includes the fact that reduction of E-cadherin may contribute to metastatic spread of breast cancer (10).

The epidermal growth factor receptor (EGFR; ErbB1) and HER2 (ErbB2), members of the ErbB receptor tyrosine kinase family, are frequently overexpressed in human malignant tumors and are known to drive tumor growth and progression (11–15). Stimulation of EGFR is associated with cell proliferation and with multiple processes involved in tumor progression, invasion, and metastasis (16, 17). Overexpression of EGFR is associated with poor prognosis and reduced overall survival in patients with lung cancer (18–20). Therefore, the EGFR signaling pathway has emerged as a promising target for cancer therapy. A number of EGFR tyrosine kinase inhibitors (TKI) that target EGFR have been developed and used successfully to treat cancer patients. For example, erlotinib, a small-molecule EGFR TKI, is used to treat non–small cell lung cancer, pancreatic cancer, and several other types of cancer (21, 22). However, in non-IBC, EGFR TKIs such as erlotinib and gefitinib have shown minimum clinical activity (23, 24). Further, when the activity of an EGFR/HER2 dual TKI, lapatinib, was tested in IBC, lapatinib exhibited clinical activity only in heavily pretreated HER2-positive IBC (25).

In our previous study, we showed that EGFR overexpression was detected in 30% of IBC patients by immunohistochemical staining. EGFR-expressing IBC was associated with a significantly worse 5-year overall survival rate than EGFR-negative IBC, and EGFR expression was associated with increased risk of IBC recurrence (26). Thus, EGFR may represent a potential therapeutic target in IBC. However, the biological association between EGFR expression and poor prognosis and increased risk of recurrence is not known in IBC, and the effect of EGFR TKIs on metastasis of IBC has not been evaluated.

In the study reported here, we found that erlotinib exhibits extracellular signal–regulated kinase (ERK)–dependent antiproliferative activity in IBC. Furthermore, erlotinib reversed the mesenchymal phenotype of IBC cells to epithelial phenotype in three-dimensional culture. More importantly, erlotinib inhibited the tumor growth and spontaneous lung metastasis of IBC in an orthotopic IBC xenograft model. Our study provides a rationale for developing novel treatment strategies targeting the EGFR and ERK pathways to inhibit the growth and metastasis of EGFR-expressing IBC.

Materials and Methods

Cell culture, reagents, and transfection. The human IBC cell line SUM149 (estrogen receptor and progesterone receptor negative; EGFR and HER2 positive) was obtained from the University of Michigan. The SUM149 cells were grown in Ham’s F-12 medium supplemented with 5% fetal bovine serum (Life Technologies, Inc.), 5 µg/mL insulin, and 1 µg/mL hydrocortisone in a humidified atmosphere containing 5% CO2 at 37°C. The KPL-4 IBC cell line (estrogen receptor and progesterone receptor positive; EGFR and HER2 positive; ref. 27) was kindly provided by Dr. Junichi Kurebayashi (Kawasaki Medical School, Kawasaki, Japan) and was maintained in DMEM/F-12 medium supplemented with 10% fetal bovine serum. Erlotinib was purchased from ChemieTek. The expression vector for hemagglutinin-tagged constitutively active (CA) mitogen-activated protein kinase/ERK kinase 1 (MEK1) was a gift from P.P. Pandolfi (Harvard Medical School, Boston, MA). Cells were transfected with CA-MEK1 using FuGENE 6 reagent (Roche). Anti-hemagglutinin antibody was used to detect the expression of CA-MEK1 in IBC cells by Western blot analysis following the approach described in our previously published article (28).

Western blot analysis. Western blot analysis was done as previously described (29). The following antibodies were used (all from Cell Signaling Technology except where indicated): anti-EGFR (Santa Cruz Biotechnology), anti-HER2 (Oncogene Research Products), anti–phospho-EGFR (Y1173; Santa Cruz Biotechnology), anti-Akt, anti–phospho-Akt (S473), anti-ERK 1/2, anti–phospho-ERK 1/2 (T202/Y204), anti-hemagglutinin (Santa Cruz Biotechnology), and anti–β-actin (Sigma-Aldrich).

WST-1 assay. A cell suspension of 2,000 cells/90 µL was seeded into each well of a 96-well plate and cultured overnight, after which 10 µL of erlotinib solution at a final concentration ranging from 0.1 to 10 µmol/L were added to the individual wells. The concentrations of erlotinib used in WST-1 assay were chosen based on our previously published article (30). After 3 d of erlotinib treatment, 10 µL of ready-to-use WST-1 [4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate] reagent (Roche Applied Science) were added directly into the medium; the plates were incubated at 37°C for 1 h; and absorbance was measured on a plate reader at 450 nm. All experiments were done in triplicate. Cell viability was calculated as the percentage of cells killed by the treatment as measured by differences in absorbance between treated and untreated wells. Median inhibitory concentrations were determined from these calculations.

Small Interfering RNA knockdown. ON-TARGET Plus siRNA SMART Pools against EGFR and ERK 1/2 and siGENOME Non-Targeting siRNA Pool [control small interfering RNA (siRNA)] were purchased from Dharmacon Research, Inc. RNA interference assay was done according to the manufacturer’s protocol (Dharmacon Research). Briefly, cells were seeded in six-well culture plates at 30% confluence in culture medium supplemented with fetal bovine serum. The next day, cells
were transfected with siRNA at a final concentration of 100 nmol/L by using Oligofectamine (Invitrogen).

Migration and invasion assay. For transwell migration assay, SUM149 cells were first treated with erlotinib for 48 h. Then 2.5 × 10^5 cells were layered in the top chambers of 24-well transwell plates (BD Biosciences; 8-μm pore size) and incubated at 37°C for 6 h in normal culture medium without erlotinib. Cells in the top chamber (non-migrated) were removed, and cells in the bottom chamber (migrated) were fixed in 20% methanol and stained with 0.1% crystal violet. For quantification, migrated cells were counted from four random fields per well from three independent experiments. The quantification of cell invasion was done using Boyden chambers. Cells were treated with erlotinib for 48 h before the assay, and 2.5 × 10^4 cells were then plated in serum-free medium in the upper chamber of the Boyden chamber coated with Matrigel (BD Biosciences), with serum-containing medium in the lower chamber in the absence of erlotinib. Twenty-four hours later, uninvaded cells were removed from the upper chamber, and the undersides of the membranes were fixed and stained. Invading cells were quantitated by dissolving stained cells in a solution of 4% sodium deoxycholate and colorimetric reading of absorbance at 595 nm.

Anchorage-independent growth. Soft agar colony-formation assay was done as previously described (31). Briefly, SUM149 cells (2 × 10^3 per well) were inoculated into soft agar (0.4%) in culture medium and then plated over a base layer of 0.8% agarose containing erlotinib in six-well culture plates and incubated for 3 wk. The plates were then stained with p-iodonitrotetrazolium violet (1 mg/mL) for 24 h at 37°C. The number of colonies of >50 cells that formed was counted.

Flow cytometry analysis. For flow cytometry analysis, SUM149 cells were plated in 60-mm dishes, cultured overnight, and then treated with or without erlotinib. After 48 h, floating and adherent cells were collected by trypsinization, fixed overnight in 70% ethanol, and resuspended in propidium iodide (25 μg/mL) supplemented with 0.1% RNase A. DNA content was measured with a FACScan flow cytometer (BD Biosciences). These experiments were repeated three times independently.

Immunofluorescence and immunohistochemical analyses. Immunofluorescence analyses were done as previously described (32). For immunofluorescence analysis, primary antibodies were anti-E-cadherin (Zymed Laboratories), anti-β-catenin (Santa Cruz Biotechnology), and anti-vimentin (Chemicon International). FITC-conjugated antibodies (Biosource) were used as secondary antibodies for vimentin.
staining, and Texas red–conjugated antibodies (Invitrogen) for E-cadherin and β-catenin staining. Cells were counterstained with 4',6-diamidino-2-phenylindole before being mounted on glass coverslips and analyzed by confocal microscopy (FV300, Olympus). For immunohistochemical analysis, tumors were fixed in 10% phosphate-buffered formaldehyde for 24 h, embedded in paraffin, and stained as previously described (32).

Three-dimensional culture. Matrigel (BD Biosciences) was stored at -80°C. Before use, Matrigel was thawed on ice overnight. For the bottom layer, 65 μL of Matrigel solution per well were added into a four-well chamber slide (Lab-Tek II, Nalge Nunc International) and incubated at 37°C for 30 min to allow the Matrigel to solidify. Then, 5 × 10⁴ cells were resuspended in 500 μL of culture medium with 2% Matrigel and erlotinib on ice and added to the solidified bottom layer.

Animal xenograft studies. All animal experiments were approved by the institutional review board of The University of Texas M.D. Anderson Cancer Center. Luciferase-expressing SUM149 (SUM149-luc) cells were established by stably transfecting pEF1a-Luc-IRES-Neo vector (33) into SUM149 cells. These cells have a phenotype and a proliferation rate similar to those of parental SUM149 cells. A total volume of 0.15 mL of SUM149-luc cell suspension containing 5 × 10⁶ cells with 50% Matrigel were injected into the bottom left mammary fat pad of 6-wk-old nu/nu mice. On day 22, mice with well-established tumors (tumor volume close to 100 mm³) were randomly allocated to four groups and were treated with 0 (vehicle, control), 25, 50, or 100 mg/kg of erlotinib daily by oral gavage for 28 d. The control-group mice received 0.5% methyl cellulose vehicle treatment. Each treatment group was composed of seven mice. Tumor volume was determined weekly by externally measuring the tumors in two dimensions using a caliper. Volume (V) was determined by the following equation, where L is length and W is width of the tumor: V = (L × W²) × 0.5. Tumor growth inhibition (%) was calculated as follows: 1 - (the tumor volume change of treatment group / the tumor volume change of control group). Anti-tumor efficacy was determined by the percentage tumor growth inhibition. Percentage tumor growth inhibition at the end point of the study was compared between the control group and each treated group.

Ex vivo luciferase imaging of mice. Metastatic tumors in lung were detected by ex vivo luciferase imaging (IVIS imaging system 100, Xenogen Corporation). Before imaging, mice were injected i.p. with 150 mg of D-luciferin (Caliper Life Sciences) per kilogram of body weight. Five minutes later, all animals were euthanized by cervical dislocation under isoflurane anesthesia, and lung tissues were collected immediately and then subjected to imaging for another 5 min. Fisher's exact test was used to determine whether there was any difference in the incidence of lung metastasis between control and erlotinib-treated groups.

Statistical analysis. Statistical analyses were done using commercially available software (Statview, version 5.0, SAS Institute). Two-sided unpaired Student's t test was used for comparison between control and treated groups. Statistical significance was defined as P < 0.05.

![Image](image-url)

Fig. 2. IBC cells are sensitive to erlotinib. A, SUM149 and KPL-4 cells were treated with 0 (vehicle), 0.01, 0.1, or 1 μmol/L erlotinib for 72 h. Western blot analysis was done to detect EGFR, p-EGFR, Akt, p-Akt, ERK, and p-ERK. β-Actin was used as a loading control. B, SUM149, KPL-4, MDA-MB-468, and BT-20 cells were plated in 96-well plates and treated with 0.1, 0.25, 0.5, 1, 2.5, 5, or 10 μmol/L erlotinib for 3 d. WST-1 assay was done to quantify the activity of erlotinib. C, SUM149 cells were treated with 0, 0.1, or 1 μmol/L erlotinib for 48 h, and FACScan analysis was done to detect the cell cycle distribution. D, SUM149 and KPL-4 cells were plated in soft agar with 0, 0.1, or 1 μmol/L erlotinib to determine anchorage-independent growth. Differences in the colony numbers were measured 21 d later. P values are indicated. Each experiment was repeated three times independently.
Results

Depletion of EGFR inhibits proliferation of IBC cells. We first tested the expression levels of EGFR and HER2 in two IBC cell lines, SUM149 and KPL-4. Western blot analysis showed that SUM149 cells have high expression of EGFR and low expression of HER2 and that KPL-4 cells have high expression of both EGFR and HER2 (Fig. 1A).

We then tested whether the EGFR pathway is intact in these two IBC cell lines by treating cells with EGF stimulation. Phosphorylation of EGFR was upregulated by EGF stimulation in both cell lines (Fig. 1B). Activation of Akt and ERK1/2, which are downstream of the EGFR pathway in cell proliferation and survival mechanisms, was also detected after EGF stimulation (Fig. 1B), suggesting that the EGFR pathway is functional in IBC cells. We then examined the effect of siRNA-mediated EGFR inhibition on IBC cell proliferation. EGFR siRNA knockdown cells proliferated much more slowly than control siRNA–treated cells, suggesting that EGFR plays an important role in the proliferation of IBC cells (Fig. 1C and D).

Erlotinib inhibits proliferation and anchorage-independent growth of IBC cells, and this inhibitory activity of erlotinib is ERK dependent. Because EGFR siRNA knockdown inhibited IBC cell proliferation, we further studied the biological effect of EGFR TKI erlotinib on IBC cells. As expected, erlotinib significantly inhibited tyrosine phosphorylation of EGFR, Akt, and ERK in SUM149 and KPL-4 cells (Fig. 2A). We then tested the erlotinib sensitivity of both EGFR-overexpressing IBC cell lines, SUM149 and KPL-4, and EGFR-overexpressing non-IBC cell lines, MDA-MB-468 and BT-20 (30), by WST-1 cell proliferation assay and found that the median inhibitory concentration (IC50) was 0.90 μmol/L for SUM149 and 2.49 μmol/L for KPL-4 cells, whereas it was >10 μmol/L for MDA-MB-468 and BT-20 cells (Fig. 2B). Thus, the EGFR-overexpressing IBC cells were much more sensitive to erlotinib than were the non-IBC EGFR-overexpressing cells. Erlotinib induced G1 cell cycle arrest in SUM149 cells by FACScan analysis (Fig. 2C). To study the effect of erlotinib on anchorage-independent growth of IBC, SUM149 and KPL-4 cells were plated in soft agar and examined for differences in colony formation. We found that erlotinib–treated cells developed much fewer colonies in soft agar than did untreated cells (Fig. 2D).

Because SUM149 cells have active EGFR pathways, we studied the role of ERK in SUM149. We induced ERK activation by transiently transfecting CA-MEK1 (28) into SUM149 cells (Fig. 3A) and then treated them with erlotinib. We found that the cell viability of CA-MEK1–transfected cells after erlotinib treatment was markedly increased compared with that of empty.
vector–transfected cells, indicating that ERK activation made SUM149 cells more resistant to erlotinib (Fig. 3B). We then performed ERK siRNA knockdown in SUM149 cells and treated them with erlotinib (Fig. 3C). We found that ERK siRNA knockdown cells were more sensitive to erlotinib than control siRNA knockdown cells (Fig. 3D). Furthermore, inhibition of ERK activity by MEK inhibitors, PD184161 and U0126, also sensitized SUM149 cells to erlotinib (data not shown). The role of ERK in another IBC cell line, KPL-4, was also studied. We performed ERK siRNA knockdown in KPL-4 cells and then treated them with erlotinib (Supplementary Fig. S1A). We found that ERK siRNA knockdown cells were more sensitive to erlotinib than were control siRNA knockdown cells (Supplementary Fig. S1B). Interestingly, even though phospho-Akt is also significantly inhibited by erlotinib treatment (Fig. 2A), inhibition of Akt activity by the phosphoinositide 3-kinase inhibitor LY29004 did not enhance the antiproliferative activity of erlotinib in SUM149 cells (Supplementary Fig. S2), suggesting that erlotinib does not inhibit IBC growth through the Akt pathway.

In summary, these data indicated that erlotinib inhibits IBC growth through the ERK pathway in both EGFR-positive SUM149 and EGFR-positive KPL-4 cells.

Erlotinib inhibits the motility and invasiveness of SUM149 cells and reverses the mesenchymal phenotype of IBC cells in three-dimensional culture. Because patients with IBC are at high risk for recurrence in the form of metastatic disease, we first examined the motility of SUM149 cells by transwell migration assay after erlotinib treatment. As expected, cell migration was significantly inhibited by both a low dose (0.1 μmol/L) and a high dose of erlotinib (1 μmol/L; Fig. 4A). Similarly, erlotinib impaired the invasion of SUM149 cells in Matrigel invasion assay (Fig. 4B). Interestingly, the inhibition of migration and invasion seen following exposure of SUM149 cells to 0.1 μmol/L erlotinib occurred in the absence of reduced cell viability.

**Fig. 4.** Erlotinib inhibits SUM149 cell motility and invasion. A, SUM149 cells were evaluated for their motility by transwell migration assay after 48-h treatment with 0, 0.1, or 1 μmol/L erlotinib and 6-h migration. The numbers of transwell-migrated cells were counted. B, SUM149 cells were treated with 0, 0.1, or 1 μmol/L erlotinib for 48 h and then subjected to an invasion assay for another 24 h and assayed for their ability to invade through Matrigel. Absorbance values at 595 nm (OD 595 nm) correspond to the low side of the filter and represent the mean of three determinations. C, transwell migration assay described in A was done in MDA-MB-468 cells. D, Matrigel invasion assay described in B was done in MDA-MB-468 cells. P values are indicated.
activity of erlotinib in migration and invasion was also examined in EGFR-overexpressing non-IBC MDA-MB-468 cells. Compared with IBC cells, the cell motility and invasiveness were not inhibited by erlotinib in MDA-MB-468 cells (Fig. 4C and D).

After confirming the inhibition of motility and invasiveness by erlotinib and because EGFR overexpression was previously found to be more metastatic in IBC patients, we hypothesized that EGFR suppression inhibits metastasis of IBC. In two-dimensional culture condition, both SUM149 and KPL-4 cells showed an epithelial phenotype characterized by localization of E-cadherin and β-catenin at sites of cell-cell contact (Fig. 5A and data not shown). When we cultured IBC cells in a three-dimensional culture system, both SUM149 and KPL-4 cells exhibited a mesenchymal-like phenotype (Fig. 5B, left). These mesenchymal-looking cells exhibited reduced expression of the epithelial marker E-cadherin and significantly increased expression of the mesenchymal marker vimentin compared with the cells in two-dimensional culture (Fig. 5C, top). However, when these cells in three-dimensional culture were treated with erlotinib, the mesenchymal-like phenotype changed to an epithelial-cell phenotype (Fig. 5B, middle and right). Interestingly, the concentration of erlotinib that reversed the mesenchymal phenotype (0.1 μmol/L) was 1 log lower than the concentration that inhibited proliferation (1 μmol/L). Erlotinib induced upregulation of E-cadherin and downregulation of vimentin and recovered β-catenin in the cell membrane in three-dimensional culture, which is consistent with the epithelial phenotype (Fig. 5C, middle and bottom). These data indicated that erlotinib can inhibit EMT of EGFR-expressing IBC cells and suggested that erlotinib might have antimetastatic activity against IBC.

Because the antiproliferative activity of erlotinib is ERK dependent, we depleted ERK by ERK siRNA knockdown in SUM149 cells and then plated the cells in three-dimensional culture. We found that ERK siRNA knockdown reversed the mesenchymal phenotype of SUM149 cells in three-dimensional culture (Fig. 5D), suggesting that ERK plays an important role in EMT of IBC.

Erlotinib inhibits tumor growth and metastasis in a SUM149 xenograft model. After observing that erlotinib reduced cell proliferation and reversed the mesenchymal phenotype of SUM149 IBC cells in vitro, we hypothesized that erlotinib inhibits tumor growth and metastasis in a SUM149 breast cancer xenograft model. To address this hypothesis, we generated a SUM149 xenograft model by implanting SUM149-luc cells into the mammary fat pads of athymic nude mice. SUM149 tumors were readily apparent in mammary fat pads after 14 days and grew rapidly. Beginning 3 weeks after tumor cell implantation, the mice were treated with erlotinib administered by oral gavage daily for another 4 weeks. To identify the optimal doses that inhibit tumor growth and/or metastasis, we treated mice with SUM149 xenografts with three different doses of erlotinib.

Fig. 5. Erlotinib reverses the mesenchymal phenotype of SUM149 cells in three-dimensional culture. A, phase-contrast picture (Phase) of SUM149 cells in two-dimensional culture. Immunofluorescence analysis was done by using anti-E-cadherin and anti–β-catenin antibodies in SUM149 cells. Nuclei were visualized with 4′,6-diamidino-2-phenylindole (DAPI). B, SUM149 (top) and KPL-4 (bottom) cells were plated in three-dimensional culture without or with erlotinib (0.1 or 1 μmol/L) and cultured for 48 h. The phenotypes were shown by using a phase-contrast microscope. C, SUM149 cells were plated in three-dimensional culture without or with erlotinib for 4 d. Immunofluorescence analysis was done to detect E-cadherin, β-catenin, and vimentin. Nuclei were visualized with 4′,6-diamidino-2-phenylindole. D, SUM149 cells were transfected with control or ERK siRNA for 48 h and then plated in three-dimensional culture for another 48 h. The phenotypes were shown by using a phase-contrast microscope. Bar, 50 μm.
25, 50, and 100 mg/kg of body weight. Treatment with 50 or 100 mg/kg/d erlotinib was chosen based on previous antitumor activity of erlotinib (34, 35).

The higher doses (50 and 100 mg/kg) of erlotinib showed significant tumor growth inhibition in the SUM149 xenograft model. On day 49, mean tumor growth inhibition was 84% in the 50 mg/kg group ($P < 0.0001$) and 103% in the 100 mg/kg group ($P < 0.0001$) compared with the control group. Some tumor growth inhibition (43%) was observed in the 25 mg/kg group, but this inhibition was not significant compared with the control group ($P = 0.06$; Fig. 6A).

To evaluate the antimitastatic activity of erlotinib in IBC, at the end point of animal study, we collected lung tissues from mice and then performed ex vivo luciferase imaging to detect spontaneous lung metastases in the mice with SUM149 xenograft tumors (Fig. 6B). The metastatic tumors in bioluminescence-positive lung tissues were further confirmed by H&E staining (Fig. 6B). Bioluminescence-positive lungs, indicating the presence of metastatic tumors, were detected in 3 of 7 (43%) mice in the control group. However, no bioluminescence-positive lungs were detected in mice in the three erlotinib-treated groups, indicating that erlotinib inhibited metastasis of IBC ($P = 0.04$; Table 1). Finally, we examined the expression of phosphorylated EGFR, phosphorylated ERK, and EMT markers in the primary tumor tissues by immunohistochemistry. As expected, the expression of phosphorylated EGFR and phosphorylated ERK was significantly inhibited in erlotinib-treated tumors compared with control tumors (Fig. 6C). More importantly, erlotinib increased the expression of E-cadherin and lowered the expression of vimentin in all erlotinib-treated tumors compared with control tumors (Fig. 6C). In conclusion, inhibition of lung metastasis and reversal from mesenchymal to epithelial phenotype were observed even in the low-dose condition (25 mg/kg erlotinib) that had no significant effect on primary tumor growth.

**Discussion**

In this report, we provide evidence that EGFR is a relevant target in IBC. Our novel finding here is that EGFR TKI erlotinib inhibited cell motility and invasiveness and reversed a mesenchymal phenotype of IBC cells to an epithelial phenotype at a low concentration that did not induce cytotoxicity (Figs. 4 and 5). This finding was further confirmed by our finding of in vivo antimitastatic activity despite limited antitumor activity at a low dose of erlotinib (Fig. 6). Erlotinib-treated tumors showed high expression of the epithelial marker E-cadherin.
and low expression of the mesenchymal marker vimentin compared with vehicle-treated tumors, suggesting that the antiproliferative activity of erlotinib may be through EMT inhibition. As expected, we found that the EGFR TKI erlotinib at a higher concentration showed dramatic antiproliferative activity against IBC both in vitro and in vivo, and this antiproliferative activity was ERK dependent.

One of our most interesting findings was that erlotinib reversed the mesenchymal phenotype to an epithelial phenotype in IBC cells in three-dimensional culture. As shown in Figs. 4 and 5B and C, we found that a low concentration of erlotinib (0.1 μmol/L) inhibited cell motility and invasion and reversed the mesenchymal phenotype to an epithelial phenotype, even though this concentration did not inhibit cell proliferation. More importantly, a low dose of erlotinib (25 mg/kg) inhibited lung metastasis in our xenograft model despite continuing growth of the primary tumors (Fig. 6). Those erlotinib-treated tumors had increased expression of E-cadherin and reduced expression of vimentin. Therefore, both our in vitro and in vivo findings suggest that a low dose of erlotinib might be able to inhibit EMT, and therefore metastasis of IBC, even if this dose does not shrink the primary tumor. Typically, efficacy in phase II cancer clinical trials is measured in terms of the effect of treatment on tumor size (tumor response) but not metastasis. Our findings reported here suggest that for drugs like erlotinib, not only tumor shrinkage but also time-dependent end points of no recurrence, which may reflect metastasis inhibition, might be used as indicators of clinical drug efficacy. Our study may prompt the development of a therapeutic approach for preventing IBC metastasis by continuously delivering low doses of EGFR TKIs such as erlotinib to IBC patients in the adjuvant setting.

The mitogen-activated protein kinase-ERK pathway is known to promote cell proliferation, differentiation, survival, and metastasis (36, 37). It has been reported that blockade of the mitogen-activated protein kinase pathway suppresses growth of colon tumors and melanoma metastasis in vivo (38, 39), supporting the therapeutic value of blocking ERK signaling in cancer. Here, we have provided evidence that the antiproliferative activity of erlotinib and conversion of mesenchymal to epithelial phenotype in IBC are ERK dependent, with ERK siRNA knockdown cells showing greater sensitivity to erlotinib. Our data suggest that combining erlotinib therapy with inhibition of the ERK pathway may improve the therapeutic outcome in IBC.

In a phase II trial of the dual HER2/EGFR TKI lapatinib in IBC patients (25), lapatinib showed clinical activity against HER2-overexpressing IBC but produced no clinical responses in EGFR-expressing, HER2-negative IBC. In agreement with those findings, we recently found in a study in which we used siRNA to knock down either EGFR or HER2 in EGFR-expressing, HER2-overexpressing non-IBC cells that lapatinib activity was dependent on HER2 activity, but not on EGFR activity, in these cells (29). In the present study, an EGFR TKI, erlotinib, showed activity not only against EGFR-expressing, HER2-overexpressing KPL-4 IBC cells but also against EGFR-expressing, HER2-negative SUM149 IBC cells. Taken together, these findings warrant further investigation of erlotinib monotherapy in EGFR-expressing IBC, regardless of HER2 status, or combination therapy with lapatinib and the HER2-targeted monoclonal antibody trastuzumab in EGFR/HER2-expressing IBC.

In conclusion, we have shown that EGFR can reverse a mesenchymal phenotype of IBC cells to a epithelial phenotype and that the EGFR TKI erlotinib can reduce metastasis of IBC, possibly through inhibition of EMT. Thus, EGFR is an important target in IBC. Our novel insights might lead to development of novel therapeutic approaches for EGFR-expressing IBC, such as targeting EGFR and the ERK pathway simultaneously to inhibit tumor growth and metastasis.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Acknowledgments
We thank Dr. Junichi Kurebayashi for providing KPL-4 cells; Linda X.H. Yuan (Department of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center) for technical assistance; and Stephanie P. Deming (Department of Scientific Publications, The University of Texas M.D. Anderson Cancer Center) for editorial assistance.

References

<table>
<thead>
<tr>
<th>Table 1. Numbers of mice with metastatic tumor and the incidence of lung metastasis in four groups</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group</td>
</tr>
<tr>
<td>Control (vehicle)</td>
</tr>
<tr>
<td>25 mg/kg erlotinib</td>
</tr>
<tr>
<td>50 mg/kg erlotinib</td>
</tr>
<tr>
<td>100 mg/kg erlotinib</td>
</tr>
</tbody>
</table>